28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Journal of The American Academy of Dermatology Année : 2021

28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Domaines

Sciences du Vivant [q-bio]

Hélène BILLARD  : Connectez-vous pour contacter le contributeur

https://hal.inrae.fr/hal-03853030

Soumis le : mardi 15 novembre 2022-11:20:41

Dernière modification le : mercredi 7 février 2024-15:26:10

Fichier non déposé

Dates et versions

hal-03853030 , version 1 (15-11-2022)

Identifiants

Citer

Andrew Blauvelt, Andreas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong, et al.. 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2). Journal of The American Academy of Dermatology, 2021, 85 (3), pp.AB177. ⟨10.1016/j.jaad.2021.06.723⟩. ⟨hal-03853030⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-NANTES INRAE PHAN NANTES-UNIVERSITE UFR-MEDECINE-NANTES
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More